Holen Sie sich die Stockscreener-App
49.02
3.22%
1.44
Schlusskurs vom Vortag:
$47.58
Offen:
$47.58
24-Stunden-Volumen:
495.93K
Relative Volume:
0.69
Marktkapitalisierung:
$3.85B
Einnahmen:
$688.00K
Nettoeinkommen (Verlust:
$-135.82M
KGV:
-23.59
EPS:
-2.078
Netto-Cashflow:
$-169.41M
1W Leistung:
+8.12%
1M Leistung:
+22.32%
6M Leistung:
+194.60%
1J Leistung:
+283.97%
1-Tages-Spanne:
$46.79
$49.85
1-Wochen-Bereich:
$46.27
$51.06
52-Wochen-Spanne:
$10.91
$51.06
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Firmenname
Spyre Therapeutics Inc
Sektor
Branche
Telefon
(617) 651-5940
Adresse
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
49.04 | 3.74B | 688.00K | -135.82M | -169.41M | -2.078 |
VRTX
Vertex Pharmaceuticals Inc
|
433.59 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.90 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.75 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.75 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.04 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Eingeleitet | Mizuho | Outperform |
| 2025-12-17 | Eingeleitet | Citigroup | Buy |
| 2025-09-26 | Eingeleitet | Deutsche Bank | Buy |
| 2025-04-08 | Eingeleitet | Leerink Partners | Outperform |
| 2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-04 | Eingeleitet | Wedbush | Outperform |
| 2024-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-05-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-12-11 | Eingeleitet | Guggenheim | Buy |
| 2023-12-11 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-04 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-14 | Bestätigt | Needham | Buy |
Alle ansehen
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
Aug Highlights: What is the implied volatility of Spyre Therapeutics Inc2026 Trends & AI Driven Stock Reports - baoquankhu1.vn
Spyre Therapeutics (NASDAQ:SYRE) CEO Cameron Turtle Sells 15,000 Shares - MarketBeat
Trading Recap: Is Spyre Therapeutics Inc stock good for income investors2026 Pullback Review & Weekly Top Performers Watchlists - baoquankhu1.vn
Insider Sell: Cameron Turtle Sells 15,000 Shares of Spyre Therap - GuruFocus
Insider Sell: Cameron Turtle Sells 15,000 Shares of Spyre Therapeutics Inc (SYRE) - gurufocus.com
Spyre therapeutics CFO sells $370k in shares By Investing.com - au.investing.com
Sloan, Spyre Therapeutics CMO, sells $397k in shares By Investing.com - Investing.com Canada
Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows Sells 7,500 Shares - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Insider Sheldon Sloan Sells 7,958 Shares - MarketBeat
Turtle Cameron, Spyre Therapeutics CEO, sells $739k in shares By Investing.com - Investing.com Canada
Spyre Therapeutics (SYRE) CFO exercises options and sells 7,500 shares under 10b5-1 plan - Stock Titan
Spyre Therapeutics (SYRE) CEO sells 15,000 shares in planned trades - Stock Titan
Spyre Therapeutics Announces Grants of Inducement Awards - manilatimes.net
Five new Spyre hires get stock options for 70,200 shares - Stock Titan
JPMorgan Chase & Co. Has $4.63 Million Stock Holdings in Spyre Therapeutics, Inc. $SYRE - marketbeat.com
Spyre Therapeutics, Inc. team assembles 1,500 kits for students during annual gathering - Traders Union
SYRE SEC FilingsSpyre Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
[144] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
Spyre Therapeutics (NASDAQ:SYRE) Hits New 1-Year HighShould You Buy? - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Receives "Buy" Rating from BTIG Research - MarketBeat
SYRE Receives Reiteration of 'Buy' Rating by BTIG | SYRE Stock N - GuruFocus
SYRE Receives Reiteration of 'Buy' Rating by BTIG | SYRE Stock News - GuruFocus
BTIG reiterates Buy on Spyre stock after J&J deal validates approach - Investing.com Canada
Is Spyre Therapeutics (SYRE) Using Faster RA Trial Timelines To Redefine Its Autoimmune Strategy? - simplywall.st
Can Spyre Therapeutics Inc grow without external fundingEarnings Risk Report & Growth Focused Entry Reports - baoquankhu1.vn
Vanguard disaggregates holdings for Spyre Therapeutics (SYRE); reports 0 shares - Stock Titan
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 5.7%Time to Buy? - MarketBeat
Spyre Therapeutics stock hits 52-week high at 45.79 USD By Investing.com - Investing.com Australia
Spyre Therapeutics (NASDAQ:SYRE) Sets New 12-Month HighHere's What Happened - marketbeat.com
Spyre Therapeutics stock hits 52-week high at 45.79 USD - Investing.com
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Assessing Spyre Therapeutics (SYRE) Valuation After Strong One Year Return And Premium Price To Book Ratio - Yahoo Finance
Spyre Therapeutics (SYRE) Receives a Rating Update from a Top Analyst - theglobeandmail.com
Spyre Therapeutics Completes First-in-Human Study of SPY001-001, De-risking Early Pipeline - TipRanks
US Market Recap: Can Spyre Therapeutics Inc lead its sector in growth - baoquankhu1.vn
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools - AOL.com
VR Adviser Increases Spyre Therapeutics Investment to $120.74MNews and Statistics - IndexBox
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means - The Motley Fool
VR Adviser Increases Stake in Spyre Therapeutics by 1 Million Shares - Intellectia AI
Signal or Noise: How VR Adviser's Acquisition of Spyre Therapeutics Impacts Fools - Bitget
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools - The Motley Fool
SYRE Stock Gets a Boost: Stifel Raises Price Target to $92 | SYR - GuruFocus
Spyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $92.00 - MarketBeat
Stifel raises Spyre stock price target to $92 on TL1A potential - Investing.com Canada
Guggenheim Sticks to Its Buy Rating for Spyre Therapeutics (SYRE) - The Globe and Mail
Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms (NASDAQ:SYRE) - Seeking Alpha
Spyre Therapeutics (SYRE) Is Up 7.3% After Accelerating SPY072 Phase 2 POC TimelineHas The Bull Case Changed? - simplywall.st
BTIG Reiterates Buy Rating for Spyre Therapeutics (SYRE) with $7 - GuruFocus
Spyre Therapeutics (SYRE) Advances RA Sub-Study with Early Resul - GuruFocus
Leerink Maintains Outperform on Spyre Therapeutics, Inc. (SYRE) March 16, 2026 - Meyka
Deutsche Bank Raises Price Target for Spyre Therapeutics on Strong Cash Position - timothysykes.com
Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Spyre Therapeutics Inc-Aktie (SYRE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sloan Sheldon | Chief Medical Officer |
Apr 01 '26 |
Option Exercise |
21.66 |
7,958 |
172,370 |
7,958 |
| Sloan Sheldon | Chief Medical Officer |
Apr 01 '26 |
Sale |
50.00 |
7,958 |
397,900 |
0 |
| Burrows Scott L | Chief Financial Officer |
Apr 01 '26 |
Option Exercise |
14.50 |
7,500 |
108,750 |
105,494 |
| Burrows Scott L | Chief Financial Officer |
Apr 01 '26 |
Sale |
49.34 |
7,500 |
370,076 |
97,994 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):